BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 31462169)

  • 1. Stereotactic Ablative Radiotherapy for Prostate Cancer-The Treatment Results of 500 Patients and Analysis of Failures.
    Miszczyk L; Namysł-Kaletka A; Napieralska A; Kraszkiewicz M; Miszczyk M; Woźniak G; Stąpór-Fudzińska M; Głowacki G; Tukiendorf A
    Technol Cancer Res Treat; 2019 Jan; 18():1533033819870815. PubMed ID: 31462169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term results and PSA kinetics after robotic SBRT for prostate cancer: multicenter retrospective study in Korea (Korean radiation oncology group study 15-01).
    Park Y; Park HJ; Jang WI; Jeong BK; Kim HJ; Chang AR
    Radiat Oncol; 2018 Nov; 13(1):230. PubMed ID: 30470253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost and whole pelvic radiotherapy for intermediate- and high-risk prostate cancer.
    Kim HJ; Phak JH; Kim WC
    Asia Pac J Clin Oncol; 2017 Feb; 13(1):21-27. PubMed ID: 26969216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CyberKnife stereotactic radiosurgery and stereotactic ablative radiation therapy of patients with prostate cancer bone metastases.
    Napieralska A; Miszczyk L; Stapor-Fudzinska M
    Neoplasma; 2016; 63(2):304-12. PubMed ID: 26774153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography.
    Kneebone A; Hruby G; Ainsworth H; Byrne K; Brown C; Guo L; Guminski A; Eade T
    Eur Urol Oncol; 2018 Dec; 1(6):531-537. PubMed ID: 31158100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic body radiotherapy in oligometastatic prostate cancer patients with isolated lymph nodes involvement: a two-institution experience.
    Ingrosso G; Trippa F; Maranzano E; Carosi A; Ponti E; Arcidiacono F; Draghini L; Di Murro L; Lancia A; Santoni R
    World J Urol; 2017 Jan; 35(1):45-49. PubMed ID: 27233779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors, efficacy, and toxicity of involved-node stereotactic body radiation therapy for lymph node oligorecurrent prostate cancer : An investigation of 117 pelvic lymph nodes.
    Cozzi S; Botti A; Timon G; Blandino G; Najafi M; Manicone M; Bardoscia L; Ruggieri MP; Ciammella P; Iotti C
    Strahlenther Onkol; 2022 Aug; 198(8):700-709. PubMed ID: 34757443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereotactic ablative radiotherapy with CyberKnife in the treatment of locally advanced prostate cancer: preliminary results.
    Fan CY; Chao HL; Huang WY; Lin CS; Chen CM; Lo CH
    Tumori; 2015; 101(6):684-91. PubMed ID: 26045107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate specific antigen kinetics following robotic stereotactic body radiotherapy for localized prostate cancer.
    Kole TP; Chen LN; Obayomi-Davies O; Kim JS; Lei S; Suy S; Dritschilo A; Collins SP
    Acta Oncol; 2015 Jun; 54(6):832-8. PubMed ID: 25467965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response.
    Jabbari S; Weinberg VK; Kaprealian T; Hsu IC; Ma L; Chuang C; Descovich M; Shiao S; Shinohara K; Roach M; Gottschalk AR
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):228-34. PubMed ID: 21183287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer.
    Jereczek-Fossa BA; Beltramo G; Fariselli L; Fodor C; Santoro L; Vavassori A; Zerini D; Gherardi F; Ascione C; Bossi-Zanetti I; Mauro R; Bregantin A; Bianchi LC; De Cobelli O; Orecchia R
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):889-97. PubMed ID: 21277113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Linac-based stereotactic body radiation therapy for low and intermediate-risk prostate cancer : Long-term results and factors predictive for outcome and toxicity.
    Franzese C; Badalamenti M; Di Brina L; D'Agostino G; Franceschini D; Comito T; Clerici E; Navarria P; Reggiori G; Mancosu P; Tomatis S; Scorsetti M
    Strahlenther Onkol; 2020 Jul; 196(7):608-616. PubMed ID: 32303782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer: toxicity profile and early oncologic outcomes.
    Hwang ME; Mayeda M; Liz M; Goode-Marshall B; Gonzalez L; Elliston CD; Spina CS; Padilla OA; Wenske S; Deutsch I
    Radiat Oncol; 2019 Aug; 14(1):136. PubMed ID: 31375119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-Dose Robotic Stereotactic Body Radiotherapy in the Treatment of Patients With Prostate Cancer: Preliminary Results in 26 Patients.
    Pontoriero A; Iatì G; Mondello S; Midili F; Siragusa C; Brogna A; Ielo I; Anastasi G; Magno C; Pergolizzi S; De Renzis C
    Technol Cancer Res Treat; 2016 Feb; 15(1):179-85. PubMed ID: 25586517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage CyberKnife-Based Reirradiation of Patients With Recurrent Prostate Cancer: The Single-Center Experience.
    Miszczyk L; Stąpór-Fudzińska M; Miszczyk M; Maciejewski B; Tukiendorf A
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818785496. PubMed ID: 29983098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience.
    Chen LN; Suy S; Uhm S; Oermann EK; Ju AW; Chen V; Hanscom HN; Laing S; Kim JS; Lei S; Batipps GP; Kowalczyk K; Bandi G; Pahira J; McGeagh KG; Collins BT; Krishnan P; Dawson NA; Taylor KL; Dritschilo A; Lynch JH; Collins SP
    Radiat Oncol; 2013 Mar; 8():58. PubMed ID: 23497695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retreatment for Local Recurrence of Prostatic Carcinoma After Prior Therapeutic Irradiation: Efficacy and Toxicity of HDR-Like SBRT.
    Fuller D; Wurzer J; Shirazi R; Bridge S; Law J; Crabtree T; Mardirossian G
    Int J Radiat Oncol Biol Phys; 2020 Feb; 106(2):291-299. PubMed ID: 31629838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiotherapy with or without androgen deprivation therapy.
    de Crevoisier R; Slimane K; Messai T; Wibault P; Eschwege F; Bossi A; Koscielny S; Bridier A; Massard C; Fizazi K
    Ann Oncol; 2010 Apr; 21(4):808-814. PubMed ID: 19825885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic body radiotherapy for prostate cancer: a preliminary report.
    Lee YH; Son SH; Yoon SC; Yu M; Choi BO; Kim YS; Jang HS; Lee SN; Jang JS; Hwang TK
    Asia Pac J Clin Oncol; 2014 Jun; 10(2):e46-53. PubMed ID: 22994564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [CyberKnife for prostate cancer patients. Update of 200 patients treatment results].
    Miszczyk L; Napieralska A; Namysł-Kaletka A; Woźniak G; Stapór-Fudzińska M; Głowacki G; Tukiendorf A
    Przegl Lek; 2017; 74(4):150-6. PubMed ID: 29696952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.